Cost-Utility Analysis of Erenumab Compared to Topiramate for Preventive Therapy of Migraine in Iran
The study concludes that preventive treatment of migraine with Erenumab, compared to Topiramate, is not cost-effective in Iran based on current prices. Therefore, for Erenumab to be considered cost-effective, a significant price reduction is necessary for its entry into the Iranian pharmaceutical market.
Authors
- Behzad Fatemi (ORCID: https://orcid.org/0000-0001-7912-7546)
- Meysam Seyedifar (ORCID: https://orcid.org/0000-0003-0426-1956)
- Hosein Mollaee
- Sadra Nadimi Parashkouhi
- Fatemeh Soleymani
Institutions
- Tehran University of Medical Sciences (IR)
Publication Details
- Journal
- Iranian journal of pharmaceutical research
- Published
- 2024-09-16
- DOI
- https://doi.org/10.5812/ijpr-146026
- Citations
- 2
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.77